TRVI

+ Watchlist + Portfolio

Trevi Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $14.18
52-Week Range: $9.28 – $20.22
Market Cap: $1.98B
P/E (TTM): —
EPS (TTM): -0.35
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.16
PEG Ratio: —
Return on Equity: -19.66%
Return on Assets: -13.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 37.28
Debt/Equity: 0.00
Total Debt: $605.00K
Free Cash Flow: $-33.28M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.66B

TRVI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$19.83M	$23.68M	$39.38M	$33.48M
Selling, General & Admin	$10.07M	$10.24M	$12.15M	$15.85M
Operating Expenses	$29.91M	$33.92M	$51.52M	$49.33M
Operating Income	-$29.91M	-$33.92M	-$51.52M	-$49.33M
EBITDA	-$27.98M	-$28.58M	-$47.79M	-$42.68M
Pretax Income	-$29.19M	-$29.10M	-$47.94M	-$42.82M
Income Tax	-$36.00K	-$32.00K	-$30.00K	-$64.00K
Net Income	-$29.15M	-$29.07M	-$47.91M	-$42.76M
Diluted EPS	-0.45	-0.29	-0.47	-0.32
Diluted Shares	64.54M	99.03M	101.97M	134.75M

TRVI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.59M	$32.40M	$34.10M	$18.91M
Current Assets	$122.62M	$87.55M	$109.43M	$191.66M
Total Assets	$123.02M	$89.40M	$110.90M	$193.44M
Current Liabilities	$13.40M	$5.82M	$10.51M	$9.75M
Long-Term Debt	$2.15M	—	—	—
Total Debt	$9.18M	$1.34M	$1.03M	$753.00K
Total Liabilities	$15.56M	$6.86M	$11.26M	$10.20M
Retained Earnings	-$210.07M	-$239.13M	-$287.05M	-$329.80M
Shareholders' Equity	$107.46M	$82.55M	$99.64M	$183.24M
Working Capital	$109.22M	$81.72M	$98.92M	$181.91M

TRVI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.18M	-$31.71M	-$38.26M	-$42.09M
Capital Expenditure	-$159.00K	-$137.00K	-$35.00K	-$12.00K
Free Cash Flow	-$28.33M	-$31.85M	-$38.29M	-$42.10M
Depreciation & Amortisation	$43.00K	$123.00K	$147.00K	$144.00K
Stock-Based Compensation	$2.33M	$2.25M	$3.59M	$5.18M
Investing Cash Flow	-$107.37M	$59.43M	-$21.53M	-$94.11M
Financing Cash Flow	$111.31M	-$7.91M	$61.48M	$121.01M
Net Change in Cash	-$24.24M	$19.81M	$1.70M	-$15.18M

TRVI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.81M	$9.39M	$10.09M	$6.19M	$9.94M	$15.15M
Selling, General & Admin	$3.66M	$4.33M	$3.83M	$4.03M	$4.97M	$5.36M
Operating Expenses	$11.47M	$13.72M	$13.92M	$10.22M	$14.91M	$20.51M
Operating Income	-$11.47M	-$13.72M	-$13.92M	-$10.22M	-$14.91M	-$20.51M
EBITDA	-$11.43M	-$13.68M	-$11.78M	-$8.30M	-$14.88M	-$20.48M
Pretax Income	-$10.35M	-$12.32M	-$11.82M	-$8.33M	-$13.21M	-$17.82M
Income Tax	-$11.00K	-$21.00K	-$15.00K	-$16.00K	-$20.00K	-$19.00K
Net Income	-$10.34M	-$12.30M	-$11.80M	-$8.32M	-$13.19M	-$17.80M
Diluted EPS	-0.09	-0.09	-0.08	-0.06	-0.09	-0.11
Diluted Shares	117.61M	130.35M	145.10M	145.50M	145.59M	156.60M

TRVI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$19.37M	$117.06M	$56.87M	$18.91M	$19.41M	$54.30M
Current Assets	$105.62M	$207.23M	$198.30M	$191.66M	$176.12M	$325.70M
Total Assets	$107.00M	$208.34M	$199.36M	$193.44M	$179.61M	$330.52M
Current Liabilities	$6.87M	$9.24M	$9.04M	$9.75M	$7.12M	$8.74M
Total Debt	$957.00K	$891.00K	$823.00K	$753.00K	$682.00K	$605.00K
Total Liabilities	$7.55M	$9.85M	$9.57M	$10.20M	$7.48M	$9.01M
Retained Earnings	-$297.38M	-$309.69M	-$321.49M	-$329.80M	-$343.00M	-$360.79M
Shareholders' Equity	$99.46M	$198.49M	$189.79M	$183.24M	$172.13M	$321.51M
Working Capital	$98.75M	$197.99M	$189.26M	$181.91M	$169.01M	$316.97M

TRVI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$13.48M	-$10.10M	-$10.88M	-$7.63M	-$16.69M	-$17.43M
Capital Expenditure	—	—	—	—	-$102.00K	-$124.00K
Free Cash Flow	-$13.48M	-$10.10M	-$10.89M	-$7.63M	-$16.79M	-$17.55M
Depreciation & Amortisation	$37.00K	$38.00K	$38.00K	$31.00K	$34.00K	$34.00K
Stock-Based Compensation	$1.21M	$1.38M	$1.24M	$1.35M	$2.19M	$3.27M
Investing Cash Flow	-$9.95M	-$2.61M	-$50.94M	-$30.61M	$16.96M	-$112.04M
Financing Cash Flow	$8.71M	$110.39M	$1.63M	$284.00K	$222.00K	$164.36M
Net Change in Cash	-$14.72M	$97.68M	-$60.19M	-$37.95M	$498.00K	$34.89M

Market Snapshot

About

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious neurologically mediated conditions. The company is advancing Haduvio, an investigational therapy for chronic pruritus associated with various underlying conditions. Trevi is working to address significant unmet medical needs in pruritus and other chronic conditions.